Skip to main content
TipRanks
Go Ultimate75% OFF

Egetis Therapeutics AB (0ABW) Share Price & Analysis

0ABW Stock Chart & Stats

kr 11.13-kr 0.01(-0.09%)
At close: 4:30 PM GMT
kr 7.5kr 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
SEK 11.12 - SEK 11.14
52-Week Range
SEK 4.04 - SEK 11.18
Previous Close
SEK 11.14
Volume
N/A
Average Volume (3M)
2.74M
Market Cap
SEK 5.17B
Enterprise Value
SEK 3.93B
Total Cash (Recent Filing)
SEK 266.50M
Total Debt (Recent Filing)
SEK 73.90M
Price to Earnings (P/E)
―
Beta
-0.83
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The stronger trailing revenue base indicates improving commercial traction and broader product adoption. If this growth continues, it can provide greater operating leverage and help the company spread its development and commercialization costs across a larger revenue stream over the next several quarters.

Manageable Leverage

Modest and improving leverage gives Egetis more balance-sheet flexibility than a heavily debt-funded biotech. Lower debt relative to equity can reduce near-term financing pressure and preserve capacity to support rare-disease development while revenue and profitability continue to mature.

Rare-disease Specialization

A focused orphan-drug strategy targets serious diseases where medical need is high and specialist expertise can be valuable. Late-stage development and commercialization may also shorten the path from clinical investment to potential recurring product revenue compared with earlier-stage portfolios.

Bears Say

Severe Cash Burn

Persistent and worsening cash outflows mean the business is not currently self-funding its operations or development programs. Continued reliance on external capital can dilute shareholders, increase financing sensitivity, and constrain strategic flexibility if funding conditions become less supportive.

Deep Operating Losses

Losses that greatly exceed revenue show that the current cost base remains materially above the company’s commercial scale. Unless revenue expands substantially or spending becomes more efficient, the resulting earnings deficit can persist and delay the transition to sustainable profitability.

Negative Returns And Equity Erosion

A deeply negative return on equity indicates that capital is currently producing substantial losses rather than durable shareholder returns. Continued equity erosion can weaken financial resilience over time and increase the importance of repeated external funding to maintain development and commercialization activities.

Egetis Therapeutics AB News

0ABW FAQ

What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest share price was kr 4.04 and its highest was kr 11.18 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is kr 5.17B.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 99 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Nov 06, 2026. The company reported -kr 0.197 earnings per share for the quarter.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.11.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,965,580 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -kr 0.197 in its last earnings report. Following the earnings report the stock price went up 0.18%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in GB:0ABW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology